De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34667183.
- Also identified by DOI 10.1038/s41467-021-26361-1 and PMC identifier 8526750.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L<sup>-1</sup> of daidzein and introducing plant glycosyltransferases in this strain results in production of bioactive puerarin (72.8 mg L<sup>-1</sup>) and daidzin (73.2 mg L<sup>-1</sup>). Our work provides a promising step towards developing synthetic yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-phased framework may be extended to engineer pathways of complex natural products in other microbial hosts.
Medical subject headings
- Flavonoids
- Saccharomyces cerevisiae